Integrative Cancer Care Program

With Intravenous Vitamin C

This study is a collaborative effort between the Jefferson-Myrna Brind Center of Integrative Medicine and the Kimmel Cancer Center at Jefferson, Thomas Jefferson University and Hospital.

Formal Title: Phase I, Open Label, Dose Escalating Study of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer. (IRB# 09D.99; Principal Investigator – Daniel A. Monti, MD)

The primary goal of this study is to test the safety and tolerability of intravenous vitamin C in combination with standard chemotherapy for newly diagnosed metastatic pancreatic cancer. Secondarily, the study will assess progression of the disease. 

Requirements

Some of the requirements include:

• Males and females who are at least 18 years of age
• Confirmed diagnosis of pancreatic adenocarcinoma
• Metastatic disease that is measurable by CT scan or MRI
• No previous chemotherapy or radiation
• Able to commit to three infusions a week for eight weeks (note that vitamin C infusions will be free of charge for study participants)

For full requirements to enter the study, contact Mike Matthews (study coordinator) at 215-503-7329 or e-mail michael.matthews@jefferson.edu.